Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Beth Boyd is active.

Publication


Featured researches published by Beth Boyd.


Nephron | 1989

Verotoxin receptor glycolipid in human renal tissue.

Beth Boyd; Clifford A. Lingwood

Infection with verotoxin producing Escherichia coli has been strongly implicated in the etiology of the hemolytic uremic syndrome (HUS). We have previously shown that this toxin specifically binds to a glycolipid receptor-globotriosyl ceramide (Gb3). We have therefore quantitated the level of this glycolipid by HPLC in human renal cortex and medulla as a function of age. We have also measured the binding of verotoxin to Gb3 isolated from each renal tissue sample. Gb3 was a major component of the glycolipid fraction of all renal samples analyzed. The levels were found to be higher in the cortex than medulla, correlating with the clinical incidence of renal lesions in HUS, but reduced in the kidneys of infants as compared to adults. Verotoxin binding was directly proportional to the renal Gb3 content. Thus, human renal tissue is a rich source of the verotoxin receptor glycolipid. However, changes in receptor concentration cannot explain the age-related incidence of HUS.


Journal of Neuro-oncology | 1998

Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells

Sara Arab; Masaji Murakami; Peter Dirks; Beth Boyd; Sherri Lynn Hubbard; Clifford A. Lingwood; James T. Rutka

Verotoxin 1 (VT1) is an E. coli toxin comprising an A subunit with N-glycanase activity, and five smaller B subunits capable of binding to the functional receptor globotriaosylceramide (Galα1-4-Galβ1-4-Glcceramide-Gb3). VT is implicated in hemorrhagic colitis and the more serious hemolytic uremic syndrome. VT1 is active against various tumor cell lines in vitro and in vivo. To extend the anti-cancer spectrum of activity of VT to human brain tumors, in the present analysis we studied the effects of VT on the growth of 6 permanent human astrocytoma cell lines. All astrocytoma cell lines analyzed express Gb3 and were sensitive to VT-1 at a dose of 50 ng/ml, but sensitivity was not proportional to the relative Gb3 concentration. VT induced apoptosis in these cells was shown by electron microscopy. Morphological evidence (nuclear shrinkage and chromatin condensation) of apoptosis could be clearly distinguished 1.5 hrs after toxin addition. Ultrastructural preservation of organelles was observed in conjunction with blebbing of the plasma membrane, condensation of chromatin within the nucleus and nuclear shrinkage. Apoptosis was also induced by the recombinant toxin B subunit alone, suggesting that the ligation of Gb3 is the primary induction mechanism. These studies indicate that verotoxin/Gb3 targetting may provide a novel basis for the inhibition of astrocytoma tumour cell growth.


Toxicology Letters | 1999

A comparison of the effects of verocytotoxin-1 on primary human renal cell cultures

Julie Williams; Beth Boyd; Anita Nutikka; Clifford A. Lingwood; Debora Barnett Foster; David V. Milford; C. Mark Taylor

Infection with verocytotoxin-producing Escherichia coli causes haemolytic uraemic syndrome (HUS). Verocytotoxin-1 (VT1) is cytopathic to renal microvascular endothelial cells in culture, supporting the hypothesis that the vasculopathy of HUS is caused directly by the toxic action of VT1 on cells. We provide evidence that VT1 inhibits protein synthesis in primary cultures of glomerular epithelial cells (GE), cortical tubular epithelial cells (CTE) and mesangial cells (MC). Using 100 pg/ml of VT1 we saw a decrease in protein synthesis to 14.3+/-1.9% in vero cells (a primate cell line), 1.7+/-0.3% in GE, 0.9+/-0.4% in CTE and 74.8+/-1.3% in MC at 24 h. The human renal epithelial cells are at least as sensitive as vero cells to the protein synthesis inhibitory effects of VT1 if not more so. Cell viability decreased in all cultures as measured by MTT reduction, neutral red incorporation and lactate dehydrogenase release and followed the same pattern of susceptibility as for protein synthesis inhibition. However, unlike vero cells, death occurred without DNA fragmentation. Cell sensitivity was greatest in cells which bound more VT1.


Journal of Biological Chemistry | 1997

Identification of the Key Protein for Zinc Uptake in Hemophilus influenzae

Desheng Lu; Beth Boyd; Clifford A. Lingwood

Very little is known about specific mechanisms for zinc accumulation and transport in bacteria. In this study a putative adhesin B in Hemophilus influenzae, the product of gene HI0119, has been identified as a periplasmic zinc-binding protein (PZP1). A pzp1-deficient mutant has been constructed which is defective for growth under aerobic conditions and grows poorly under anaerobic conditions. The growth defect is specifically rescued by supplementing the growth medium with high concentrations of zinc. Subcellular fractionation was used to localize PZP1 to the periplasmic region in a nontypeable H. influenzae strain and in a transfected recombinant Escherichia coli strain (TApzp1). Recombinant PZP1, purified from a periplasmic extract of E. coli strain TApzp1, contained ∼two zinc atoms/protein molecule as determined by neutron activation analysis and atomic absorption spectroscopy. The zinc atoms could be removed by incubation with EDTA, and, by further addition of zinc, a total of five zinc atoms/PZP1 could be bound. Direct binding of 65Zn to the recombinant protein by Western blot was demonstrated. Taken together, these results provide direct evidence that PZP1 plays a key role in zinc uptake by H. influenzae.


Journal of Biological Chemistry | 1993

Endothelial heterogeneity in Shiga toxin receptors and responses.

T G Obrig; C B Louise; Clifford A. Lingwood; Beth Boyd; L Barley-Maloney; T O Daniel


Infection and Immunity | 1993

Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro.

Susan A. Kaye; Chandra B. Louise; Beth Boyd; Clifford A. Lingwood; Tom G. Obrig


FEBS Journal | 1994

Lipid modulation of glycolipid receptor function

Beth Boyd; Göran Magnusson; Zhang Zhiuyan; Clifford A. Lingwood


Infection and Immunity | 1995

Shiga Toxin-Associated Hemolytic Uremic Syndrome: Effect of Sodium Butyrate on Sensitivity of Human Umbilical Vein Endothelial Cells to Shiga Toxin

Chandra B. Louise; Susan A. Kaye; Beth Boyd; Clifford A. Lingwood; Tom G. Obrig


Methods in Enzymology | 2000

[38] - Analysis of Interactions between Glycosphingolipids and Microbial Toxins

Clifford A. Lingwood; Beth Boyd; Anita Nutikka


Cellular and Molecular Biology | 2001

MHC class II proteins contain a potential binding site for the verotoxin receptor glycolipid CD77.

Tricia George; Beth Boyd; Marcia Price; Clifford A. Lingwood; Mark Maloney

Collaboration


Dive into the Beth Boyd's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge